Back to Journals » Infection and Drug Resistance » Volume 16

Prediction of 30-Day Mortality Using the Quick Pitt Bacteremia Score in Hospitalized Patients with Klebsiella pneumoniae Infection [Letter]

Authors Yang H, Huang S, Wang J

Received 7 August 2023

Accepted for publication 10 August 2023

Published 22 August 2023 Volume 2023:16 Pages 5547—5548

DOI https://doi.org/10.2147/IDR.S434294

Checked for plagiarism Yes

Editor who approved publication: Professor Suresh Antony



Huiyan Yang,1 Shengqi Huang,2 Jing Wang1

1Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of China; 2Department of Traditional Chinese Medicine, Yongning County People’s Hospital, Yongning, Ningxia, 750001, People’s Republic of China

Correspondence: Huiyan Yang, Email [email protected]


View the original paper by Dr Su and colleagues

A Response to Letter has been published for this article.


Dear editor

We are documenting this to express our appreciation for the recent publication of the research article entitled Prediction of 30-Day Mortality Using the Quick Pitt Bacteremia Score in Hospitalized Patients with Klebsiella pneumoniae Infection by Su et al1 in the reputable journal “Infection and Drug Resistance”. Firstly, I would like to congratulate the authors and acknowledge their successful publication.

The authors did fantastic work, and the findings of the study have important clinical relevance as they highlight the effects of qPitt (a simplified quicker version of the Pitt bacteremia score (PBS)), in patients with K. pneumoniae infection, and qPitt revealed excellent 30-day mortality prediction ability. The qPitt also exhibited mortality discrimination ability in nonbacteremic patients with K. pneumoniae infections.2

To one’s regret, the study does not furnish the optimal cut-off value for PBS. Studies have shown that PBS score is an index to evaluate the severity of acute infectious diseases. It was originally used to predict the mortality of patients with Pseudomonas aeruginosa bloodstream infection and has since been proved to be a good predictive value for the risk of death of patients with other gram-negative, gram-positive, antibiotic-resistant bacteria and fungal bloodstream infections, with a range of 0 to 14 points. It is common that the PBS score ≥ 4 is used to indicate an increased risk of critical illness and mortality. Through ROC curve analysis, Wang et al3 found that patients with PBS≥6 and blood infection had an increased risk of death, and this critical value reminded clinicians to be vigilant. Shen et al4 also found that the higher the PBS score, the more serious the condition of patients. The PBS value can reflect the severity of the disease, so the author believes that the threshold value of PBS score is very important.

The article draws that qPitt revealed excellent 30-day mortality prediction ability. If a critical value can be studied, it will provide clinicians with more accurate reference value.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Su C, Tsai IT, Lai CH, Lin KH, Chen CC, Hsu YC. Prediction of 30-day mortality using the quick Pitt bacteremia score in hospitalized patients with Klebsiella pneumoniae infection. Infect Drug Resist. 2023;16:4807–4815. doi:10.2147/IDR.S420569

2. Tong H, Shao B, Liu Y, et al. Evaluation value of Pitt bacteremia score in prognosis of patients with pan-drug-resistant Klebsiella pneumoniae bloodstream infection. Chine J Em Med. 2023;32(1):89–94.

3. Wang F, Zhou H, Y YAO, et al. Risk factors and prognosis of patients with fluconazole insensitive Candida tropicalis bloodstream infection. Chine J Tuberculosis Respir. 2019;42(6):459–461.

4. Shen Z, Lin S, Du X, et al. Clinical characteristics and prognostic factors of hospital-acquired Klebsiella pneumoniae bloodstream infection. Chine J Exp Clin Infect Dis. 2020;14(3):198–205.

Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.